Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Equipment >

Avant Diagnostics (AVDX)

Add AVDX Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 6/23/2017 11:50:11 AM - Followers: 40 - Board type: Free - Posts Today: 0

March 7,2016

Avant Diagnostics (OTCQB: AVDX), a biotechnology company focused on the development of oncology based diagnostics, and Amarantus Diagnostics, a wholly-owned subsidiary of Amarantus BioScience Holdings, Inc. (OTCQX: AMBS), today announced that the companies have jointly entered into a letter of intent for Avant to acquire Theranostics Health Incorporated ("THI"), adding key CLIA laboratory and intellectual property capabilities to Avant and Amarantus' previously announced diagnostics merger. Theranostics currently generates over $1.5M in services revenue from some of the world's leading biopharmaceutical companies, including 7 of the top 10 pharmaceutical companies by revenue.

Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.

OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.

As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market.


Investment Highlights

  • Developing Specialized, Cutting-Edge Medical Tests
    Advancing First-of-its-Kind Panel Biomarker Screening Test
    Detecting Pre-Symptomatic Ovarian Cancer Faster Than Ever
    Progressing on Goal to Obtain FDA 510(k) Clearance for OvaDx®



The market's first large panel biomarker screening test for ovarian cancer

OvaDx® is a sophisticated microarray-based test that measures the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.

Research studies with OvaDx® indicate high sensitivity and specificity for all types and stages of ovarian cancer including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma.

Upon FDA approval, Avant Diagnostics will offer OvaDx® as an elective test for women seeking greater wellness and for women in the elevated risk category for ovarian cancer. OvaDx® will be used by doctors to advance the forefront of ovarian cancer treatment including improved surgical options, more effective chemotherapies, and to supplement existing tests including CA-125, OVA1® and transvaginal ultrasound.

Clinicians will appreciate the following features of this product:

  • Market's first large panel screening test for ovarian cancer
    Use an elective screen for women seeking greater wellness
    Screen women at elevated risk for ovarian cancer
    High sensitivity and specificity for all types and stages of ovarian cancer
    Identifies stage I, II, III and IV disease markers in patient samples
    Detects stage IA disease markers with ~80% sensitivity and 100% Specificity
    Detects borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous, and ovarian adenocarcinoma in patient sera
    Multi-plexed microarray assay reads approximately 100 proteomic biomarkers
    Proteomic panel provides definitive real-time test results
    Microarray format reduces serum requirement to 0.1-0.25 ml per sample run
    Arrayit Diagnostics' blood cards can also be used for sample collection
    Fluorescence detection ensures high signal detectivity
    Test controls eliminate experimental false positives and false negatives
    High-throughput format scales to any number of patient samples
    Automated process permits large-scale (e.g. 1,000,000 sample+) screening
    Supplement OVA1® and other multi-analyte tests
    Supplement single marker tests including cancer antigen 125 (CA-125) and human epididymis protein (HE4)
    Supplement genetic tests including BRCA1 and BRCA2
    Supplement imaging techniques including transvaginal ultrasound, computerized tomography (CT) scans and X-rays
    Screen patient sera from breast, cervical, uterine and other cancer patients
    Test samples from patients with ovarian cysts and other benign conditions


Ovarian Cancer

The Dire Need for Early Detection of the "Silent Killer"

Ovarian cancer is the 11th most common cancer among women and the fifth-leading cause of cancer-related death among women. According to the Centers for Disease Control, Ovarian cancer causes more deaths than any other cancer of the female reproductive system, but accounts for only about 3% of all cancers in women. When ovarian cancer is found in its early stages, treatment is most effective.

Often called "the silent killer," however, ovarian cancer is rarely caught early. Many times there are no symptoms until the disease has progressed to advanced stages. About 20% of ovarian cancers are found at an early, localized stage, and 94% of those patients live longer than five years after diagnosis, according to the American Cancer Society.

While regular women's health exams, knowledge of symptoms and risks, and screenings can be important ways to detect ovarian cancer, there is much research being done to develop new tests to accurately diagnose the disease at an early stage.



Avant Diagnostics' progression toward FDA approval and commercialization of OvaDx® is spearheaded by a management team with a rich history of experience in executive leadership, accounting, corporate sales, marketing and financing for numerous industries.

Gregg Linn | President/CEO

Gregg Linn joined Avant Diagnostics as president and CEO in February December 2015. Prior to these roles, Linn served as the company's COO and CFO since December 2012. Since 2008, Linn served as the president and managing member of Issuers Capital Advisors, LLC, and since 2001 served as CEO and managing member of Red Rock Advisors, LLC. Both firms specialize in providing strategic financial and business development advisory services to public and non-public companies, with emphasis on capital formation, mergers and acquisition and management of the public side of small cap publicly traded companies. From 2004 to 2007, he was COO and CFO of Vital Living, Inc., a Phoenix, Arizona-based publicly traded nutritional supplements company. Prior to 2004, Linn served as CFO of several other public and privately held companies, senior financial management positions at Fortune 500 companies, as well as worked as a senior analyst at Shearson Lehman. Linn received an undergraduate degree in accounting and business from Michigan State University in 1984 and a Master Degree in Business Administration, summa cum laude, from Pace University-NYC in 1992. Linn is a certified public accountant.

Joseph Roth

Joseph Roth has spent more than three decades as a corporate sales, marketing and management executive with Fortune 50 companies as well as entrepreneur opportunities. For the past five years he has been self employed as a consultant to small and medium sized companies and C-level executives. From 2008-2010, he was COO of ShopBox, LLC, a business process outsourcing company specialized in the execution of web-based kiosk marketing strategies. He was responsible for securing partnership deals with NASCAR, NFL, NHL and NBA leagues, teams and franchises. From 2003 to 2008, Roth was president of CMB Franchising, Inc., a licensed Area Developer of Extreme Pita Restaurants of Canada for Arizona and Nevada. During this time he oversaw the construction, development and operations of 10 stores generating a 25% increase over the second highest volume franchise in the U.S. From 1996-2003, Roth was managing partner of Cypress Staffing Services, LLC, a company he founded in 1999 that provides private duty home care throughout Central Arizona. Cypress grew from scratch to become the largest company in Arizona within its industry category in less than four years.

Randall Letcavage

Randall Letcavage brings in excess of 25 years of business experience specializing in the financial markets, investment banking and business consulting. Currently, Letcavage is chairman, CEO, and president of Premier Holding Corp., which is publicly traded on the OTCQB exchange. For the past 20 years Letcavage has been an investment banker widely recognized for numerous achievements as well as his role of founder, officer and director of the iCapital Group, which includes iCapital Finance Inc, iCapital Advisory LLC and iCap Development LLC (A National "CDE" Community Development Entity – Certified by the U.S. Treasury Department). Letcavage has advised numerous clients on various transactions and financings in a wide range of industries, including technology, healthcare, financial services, entertainment, energy and green initiatives.


Avant Diagnostics, Inc
8561 E. Anderson, Suite 104
Scottsdale, AZ 85255

QualityStocks Investor Relations
3370 N. Hayden Rd. Suite 123-591
Scottsdale, AZ 85251
Phone: (480) 374-1336


Please see disclaimer on the QualityStocks website:

Daily Chart

Weekly Chart


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AVDX News: Current Report Filing (8-k) 06/21/2017 06:04:20 AM
AVDX News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 12/30/2016 06:08:43 AM
#933   Wow!! NEW...Arrayit reports $71,500 microarray technology sale to a UndervaluedStocks 06/23/17 11:50:10 AM
#932   The stock has been deader than a door IPO$ 06/21/17 12:31:13 PM
#931   Looks like he has plenty of relevant experience MikeCr 06/21/17 12:28:01 PM
#930   Is Gerald behind this? IPO$ 06/21/17 10:46:14 AM
#929   Looks good but why would he go back IPO$ 06/21/17 10:45:28 AM
#928   But the Press Release about the new CEO MikeCr 06/21/17 10:32:47 AM
#927   news out but stock not even current and mikekrane 06/21/17 10:13:14 AM
#926   What the hell was that 8-K all about IPO$ 06/21/17 09:44:25 AM
#924   Wow what a disaster!! bgrass1 06/07/17 10:04:39 AM
#923   As I correctly predicted AVDX's worthless POS bgrass1 05/15/17 01:01:49 PM
#922   I contacted a law firm about a suit. sonofkatz 04/16/17 11:50:56 PM
#921   LINDENBERG v. AVANT. The settlement conference in this MikeCr 03/21/17 10:14:12 AM
#919   Why don't you get one going Easy? MikeCr 02/01/17 09:42:47 AM
#918   Hey Mike, when is ARYC going to get Easymoneyman00 01/31/17 11:53:52 PM
#917   Dividend hasn't reached shareholders? ARYC is holding our Easymoneyman00 01/31/17 11:46:58 PM
#916   I thought Theranos is going out of business? nwsun 01/13/17 02:58:08 AM
#915   Nice day here Fireman451 01/04/17 11:39:29 PM
#914   .35 today :) UndervaluedStocks 01/04/17 06:15:49 PM
#913   But before that, it goes to .30 first UndervaluedStocks 01/03/17 08:31:05 PM
#912   Sorry to tell everyone here but this stock Easymoneyman00 12/12/16 12:16:26 AM
#911   Great news Mike. Been so busy on UndervaluedStocks 11/28/16 08:26:26 AM
#909   This is laughable nonsense!! bgrass1 11/10/16 07:01:46 AM
#908   Item 8.01 Other Events MikeCr 11/09/16 07:46:09 PM
#907   "The Court will grant counsels request to adjourn MikeCr 11/09/16 07:45:20 PM
#906   What was this case about? bgrass1 11/02/16 07:05:17 AM
#905   Lindenberg v. Avant settlement conference scheduled for 11/14/2016 MikeCr 10/30/16 03:33:06 PM
#904   AVDX is now "OTC Pink Limited Information" because MikeCr 10/26/16 10:35:11 AM
#903   Thought you knew everything? Fireman451 10/21/16 11:17:06 AM
#902   Is something up? bgrass1 10/20/16 01:03:59 PM
#901   I am surprised that this POS stock has bgrass1 10/07/16 11:10:14 AM
#900   A combination of (1) and (2). bgrass1 10/03/16 08:45:32 AM
#899   Scenario: Nothing happens sonofkatz 10/01/16 05:22:44 PM
#898   Nice day here Fireman451 09/26/16 08:24:10 PM
#897   How the hell do you trade 74 shares bgrass1 09/22/16 05:22:13 PM
#896   Nice day here Fireman451 09/19/16 03:50:53 PM
#895   Nice day here. Something up with aryc and Fireman451 09/16/16 07:34:45 PM
#894   Looking good over here! UndervaluedStocks 09/16/16 06:16:52 PM
#893   Ok boys lets keep an eye out for bgrass1 09/09/16 08:21:21 AM
#892   Ok by my reckoning AVDX is now in bgrass1 09/06/16 06:58:43 PM
#891   By my reckoning AVDX has to file the bgrass1 09/04/16 11:08:41 AM
#890   And why should any of us be surprised?!! bgrass1 08/28/16 08:09:11 AM
#889   They are 8 days late filing the late 10Q MikeCr 08/26/16 07:04:05 PM
#888   They are 8 days late filing the late 10Q MikeCr 08/26/16 07:03:59 PM
#887   Not sure Fireman451 08/21/16 07:09:00 PM
#886   What ever happened to the assets they acquired Cueva 08/21/16 06:22:00 PM
#885   No Fireman451 08/16/16 11:47:29 PM
#884   Anyone in a chatroom? ASH311 07/20/16 03:24:17 AM
#883   AVDX..HA,HA,HA...AS.USUAL..I'M ASKING FOR PATIENCE..ALOT GOING ON! tm1119 07/18/16 02:30:22 PM
#882   Hmmmm....very interesting!! bgrass1 07/18/16 08:30:41 AM